theophylline has been researched along with sparfloxacin in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (33.33) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 3 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Hasegawa, T; Kuzuya, T; Nadai, M; Takagi, K; Yamaki, K | 1 |
Chiba, K; Egawa, H; Fujita, M; Kataoka, M; Matsumoto, J; Minamida, A; Miyamoto, T; Nishimura, Y; Okada, H; Shibamori, K | 1 |
Fujiwara, I; Mizuki, Y; Yamaguchi, T | 1 |
1 review(s) available for theophylline and sparfloxacin
Article | Year |
---|---|
Pharmacokinetic interactions related to the chemical structures of fluoroquinolones.
Topics: Aluminum Hydroxide; Animals; Anti-Infective Agents; Caffeine; Drug Interactions; Fluoroquinolones; Humans; Molecular Structure; Quinolones; Rats; Structure-Activity Relationship; Theophylline | 1996 |
1 trial(s) available for theophylline and sparfloxacin
Article | Year |
---|---|
Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients.
Topics: 4-Quinolones; Aged; Anti-Infective Agents; Asthma; Biological Availability; Chromatography, High Pressure Liquid; Drug Evaluation; Drug Interactions; Female; Fluoroquinolones; Humans; Male; Middle Aged; Theophylline | 1991 |
7 other study(ies) available for theophylline and sparfloxacin
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Interactions; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Molecular Conformation; Phenylbutyrates; Pseudomonas Infections; Rats; Streptococcal Infections; Structure-Activity Relationship; Theophylline; X-Ray Diffraction | 1990 |